XTL Biopharmaceuticals Ltd.
XTLBNASDAQHealthcare● Active
$2.23
+$0.17(+8.25%)
Market Cap$5275304
P/E Ratio—
52W High$10.28
52W Low$2.08
XTL Biopharmaceuticals Ltd. (XTLB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · XTLB · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.45M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.45M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.00M | $0.00M | ($0.00M) | ($0.00M) | ($0.00M) |
| Gross Margin %(computed) | 0.67% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.10M | $0.03M | $0.03M | $0.03M | $0.04M |
| G&A Expenses | $1.87M | $0.73M | $0.85M | $1.00M | $0.91M |
| Total Operating Expenses | $2.17M | $0.77M | $0.88M | $1.03M | $0.95M |
| Operating Income | ($2.17M) | ($0.77M) | ($0.88M) | ($1.03M) | ($0.95M) |
| Operating Margin %(computed) | -481.60% | — | — | — | — |
| Interest Income | $0.03M | $0.04M | $0.04M | $0.01M | $0.03M |
| Interest Expense | $0.09M | $0.00M | $0.01M | $0.02M | $0.02M |
| Income Before Tax | ($1.16M) | ($1.78M) | ($1.35M) | $0.43M | ($2.95M) |
| Income Tax Expense | ($0.13M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($1.03M) | ($0.00M) | ($1.35M) | $0.43M | ($0.78M) |
| Net Margin %(computed) | -227.72% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-9.60 | $0.00 | $-16.00 | $5.12 | $-36.48 |
| Wtd Avg Shares | 0.11M | 0.09M | 0.09M | 0.08M | 0.08M |
| EBITDA | ($0.93M) | ($0.76M) | ($0.88M) | ($1.03M) | ($0.95M) |
| EBITDA Margin %(computed) | -206.21% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more XTL Biopharmaceuticals Ltd. data
About XTL Biopharmaceuticals Ltd. (XTLB) Income Statement
XTL Biopharmaceuticals Ltd. (XTLB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, XTLB reported revenue of $0.00B, gross profit of $0.00B (gross margin 0.67%), and net income of ($0.00B) — a net profit margin of -227.72%.
Frequently asked questions
XTLB · 4 questionsXTL Biopharmaceuticals Ltd. (XTLB) reported revenue of $0.00B for 2024, up —% year-over-year.
XTLB revenueXTLB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08